Bristol-Myers Squibb (NYSE:BMY) Trading Down 1.5%

Bristol-Myers Squibb (NYSE:BMYGet Free Report) traded down 1.5% during trading on Wednesday . The company traded as low as $40.92 and last traded at $41.11. 4,902,526 shares changed hands during trading, a decline of 68% from the average session volume of 15,510,286 shares. The stock had previously closed at $41.75.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Barclays dropped their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. BMO Capital Markets dropped their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Finally, StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 23rd. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $60.00.

Check Out Our Latest Stock Report on BMY

Bristol-Myers Squibb Price Performance

The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The stock has a market capitalization of $83.35 billion, a P/E ratio of -13.26, a price-to-earnings-growth ratio of 14.14 and a beta of 0.43. The firm has a 50-day moving average price of $46.26 and a 200 day moving average price of $49.14.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company’s revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the company earned $2.05 EPS. On average, analysts expect that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Hedge Funds Weigh In On Bristol-Myers Squibb

Several institutional investors and hedge funds have recently bought and sold shares of BMY. Norges Bank bought a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $1,560,524,000. Capital International Investors grew its position in Bristol-Myers Squibb by 14.1% during the 1st quarter. Capital International Investors now owns 70,203,814 shares of the biopharmaceutical company’s stock worth $3,807,153,000 after acquiring an additional 8,675,322 shares during the last quarter. M&G Plc bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $392,608,000. Pzena Investment Management LLC grew its position in shares of Bristol-Myers Squibb by 119.8% in the 1st quarter. Pzena Investment Management LLC now owns 12,293,913 shares of the biopharmaceutical company’s stock worth $666,699,000 after buying an additional 6,701,097 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Bristol-Myers Squibb by 77.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,547,823 shares of the biopharmaceutical company’s stock worth $680,469,000 after buying an additional 5,461,767 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Company Profile

(Get Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Further Reading

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.